Best Podium and Poster Presentations Awarded at ISPOR 20th Annual European Congress

Article ID: 684345

Released: 8-Nov-2017 11:05 AM EST

Source Newsroom: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Glasgow, Scotland, UK—8 November 2017—ISPOR, the professional society for health economics and outcomes research (HEOR), recognized the Best Podium and Poster Presentation Awardees from its 20th Annual European Congress held in Glasgow, Scotland, UK 4-8 November 2017. ISPOR’s Research Presentation Podium and Poster Awards were established in 1998 to recognize the scientific merit of podium and poster presentations at the Society’s Annual European Congresses, Annual International Meetings, Asia-Pacific Conferences, and Latin America Conferences.

BEST POSTER—GENERAL 

PCN177: COST UTILITY ANALYSIS (CUA) OF NIVOLUMAB COMPARED TO EVEROLIMUS FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (RCC) IN AUSTRALIA
Hansoo Kim, Bristol-Myers Squibb Australia, Mulgrave, Australia 

PMS13: RISK OF MAJOR OSTEOPOROTIC FRACTURE (HIP, VERTEBRAL, RADIUS, HUMERUS [MOF]) AFTER FIRST, SECOND AND THIRD FRAGILITY FRACTURE IN A SWEDISH GENERAL POPULATION COHORT
Emma Jonsson, Quantify Research, Stockholm, Sweden 

PMD58: CONTINUOUS SUBCUTANEOUS INFUSION VERSUS MULTIPLE DOSE INJECTION OF INSULIN FOR NEWLY-DIAGNOSED T1D PAEDIATRIC PATIENTS: A COST-UTILITY ANALYSIS
Colin H Ridyard, Bangor University, Bangor, UK 

 

BEST POSTER—STUDENT 

PCN249: SUBJECTIVE FINANCIAL BURDEN AMONG GERMAN CANCER PATIENTS - RELATIONSHIP OF THE PATIENTS’ ECONOMIC SITUATION AND SUBJECTIVE DISTRESS
Julian Witte, Bielefeld University, School of Public Health, Bielefeld, Germany 

PMH28: INTERNET BASED TREATMENT OF DEPRESSIVE SYMPTOMS – A HEALTH ECONOMIC EVALUATION OF COSTS AND BENEFITS
Viola Gräfe, School of Public Health, Bielefeld University, Bielefeld, Germany 

PSY43: BURDEN OF RENAL TRANSPLANT AMONG A COHORT OF US MEDICARE BENEFICIARIES WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
Laura A. Clark, University of North Carolina at Charlotte, Charlotte, NC, USA 

 

BEST POSTER–NEW INVESTIGATOR 

PCV34: SURVIVAL DIFFERENCES IN HEART FAILURE PATIENTS WITH AND WITHOUT IRON DEFICIENCY/ANEMIA AND BY ORAL AND INTRAVENOUS IRON TREATMENT
Julia Altevers, Xcenda GmbH, Hannover, Germany 

PMD156: DOES THE NICE DIAGNOSTICS ASSESSMENT PROGRAMME USE AN EMPIRICAL ICER THRESHOLD?
Gengshi Chen, Costello Medical Consulting Ltd, Cambridge, UK 

PRM157: PREDICTING EQ-5D INDEX SCORES FROM PROMIS PROFILE 29 IN THE UNITED KINGDOM, FRANCE, AND GERMANY
Christoph Paul Klapproth, Charité Universitätsmedizin Berlin, Berlin, Germany 

 

BEST PODIUM—GENERAL 

AD4: PREDICTIVE ANALYSIS FOR IDENTIFYING PATIENT CHARACTERISTICS ASSOCIATED WITH PRIMARY MEDICATION NONADHERENCE FOR LIPID LOWERING THERAPIES
Pallavi B Rane, Amgen Inc., Thousand Oaks, CA, USA 

SY1: PSORIASIS DRUGS IN EUROPE - MARKET ACCESS DECISIONS IN COMPARISON BASED ON THE PRISM ACCESS DATABASE
Lutz Vollmer, MArS- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany 

AD1: EXPLORING FACTORS EXPLAINING TREATMENT ACCEPTANCE IN PATIENTS SUFFERING FROM A CHRONIC DISEASE
Benoit Arnould, Mapi, Patient Centered Outcomes, Lyon, France 

 

BEST PODIUM—STUDENT 

IN4: COST-EFFECTIVENESS OF ADDITIONAL VACCINATION OF BOYS AGAINST HPV IN GERMANY
Oliver Damm, School of Public Health, Bielefeld University, Bielefeld, Germany 

CV2: A FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF NOVEL BIOMARKER TESTING IN CARDIOVASCULAR DISEASE
Ciaran N. Kohli-Lynch, University of Glasgow, Glasgow, UK 

IN2: COST-EFFECTIVENESS AND MODELING APPROACHES OF DIRECT-ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC LITERATURE REVIEW
László Szilberhorn, Eötvös Loránd University (ELTE), Budapest, Hungary

 

BEST PODIUM—NEW INVESTIGATOR 

AD3: FACTORS ASSOCIATED WITH AN ADHERENCE WITH ANTIEPILEPTIC DRUGS IN CHILDREN TREATED IN PEDIATRIC PRACTICES IN GERMANY
Silvia Dombrowski, QuintilesIMS, Frankfurt am Main, Germany 

PP2: CHOICE OF INSTRUMENT IMPACTS HEALTHCARE DECISIONS: EFFECT OF SOURCE OF UTILITY DERIVED FROM THE SAME PATIENT POPULATION ON COST-EFFECTIVENESS
Necdet B Gunsoy, GSK, Uxbridge, UK 

PP1: MIMICKING REAL LIFE DECISION-MAKING IN HEALTH: ALLOWING RESPONDENTS TIME-TO-THINK IN A DISCRETE CHOICE EXPERIMENT
J Veldwijk, Erasmus University Rotterdam, Rotterdam, The Netherlands

 

Additional information on the ISPOR 20th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the congress on social media using the hashtag #ISPORGlasgow.
 

###

 

ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT | Facebook: http://bit.ly/ISPOR-FB

SEE ORIGINAL STUDY


Comment/Share





Chat now!